HM-Chromanone Ameliorates Hyperglycemia and Dyslipidemia in Type 2 Diabetic Mice.
Jae Eun ParkJaemin SonYoungwan SeoJi Sook HanPublished in: Nutrients (2022)
The effects of ( E )-5-hydroxy-7-methoxy-3-(2-hydroxybenzyl)-4-chromanone (HMC) on hyperglycemia and dyslipidemia were investigated in diabetic mice. Mice were separated into three groups: db/db, rosiglitazone and HMC. Blood glucose or glycosylated hemoglobin values in HMC-treated mice were significantly lower compared to db/db mice. Total cholesterol, LDL-cholesterol, and triglyceride values were lower, and HDL-C levels were higher, in the HMC group compared to the diabetic and rosiglitazone groups. HMC markedly increased IRS-1 Tyr612 , Akt Ser473 and PI3K levels and plasma membrane GLUT4 levels in skeletal muscle, suggesting improved insulin resistance. HMC also significantly stimulated AMPK Thr172 and PPARα in the liver, and ameliorated dyslipidemia by inhibiting SREBP-1c and FAS. Consequently, HMC reduced hyperglycemia by improving the expression of insulin-resistance-related genes and improved dyslipidemia by regulating fatty acid synthase and oxidation-related genes in db/db mice. Therefore, HMC could ameliorate hyperglycemia and dyslipidemia in type 2 diabetic mice.
Keyphrases
- insulin resistance
- high fat diet induced
- skeletal muscle
- blood glucose
- type diabetes
- adipose tissue
- metabolic syndrome
- fatty acid
- signaling pathway
- high fat diet
- low density lipoprotein
- polycystic ovary syndrome
- cell proliferation
- diabetic rats
- poor prognosis
- blood pressure
- wild type
- nitric oxide
- oxidative stress
- high resolution
- mass spectrometry
- long non coding rna
- high speed
- atomic force microscopy
- single molecule